| Literature DB >> 25437186 |
Aditya K Gupta1, Deanne Daigle.
Abstract
Systemic antifungal treatments are believed to be more effective than topicals for the treatment of onychomycosis; however, they are associated with more risks of adverse events. Tavaborole is the first member of a new class of antifungals that has been developed as a new topical nail solution for the treatment of toenail onychomycosis caused by dermatophytes. During Phase I-III clinical trials, tavaborole 5.0% nail solution showed a favorable safety and efficacy profile. Tavaborole 5.0% received US FDA market approval on 8 July 2014.Entities:
Keywords: antifungal; benzoxaborole; dermatophytes; onychomycosis; toenail; topical
Mesh：
Substances：
Year: 2014 PMID： 25437186 DOI： 10.2217/fmb.14.76
Source DB: PubMed Journal: Future Microbiol ISSN： 1746-0913 Impact factor: 3.165